BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35982631)

  • 1. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
    Alosaimy S; Lagnf AM; Hobbs ALV; Mubarez M; Kufel WD; Morrisette T; Polisetty RS; Li D; Veve MP; Simon SP; Truong J; Finch N; Venugopalan V; Rico M; Amaya L; Yost C; Cubillos A; Chandler E; Patch M; Smith IMK; Biagi M; Wrin J; Moore WJ; Molina KC; Rebold N; Holger D; Kunz Coyne AJ; Jorgensen SCJ; Witucki P; Tran NN; Davis SL; Sakoulas G; Rybak MJ
    Clin Infect Dis; 2023 Feb; 76(3):e1444-e1455. PubMed ID: 35982631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
    Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
    Robertson AD; Li C; Hammond DA; Dickey TA
    Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin.
    Rutter WC; Burgess DS
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of combining vancomycin with piperacillin/tazobactam or with meropenem on vancomycin-induced nephrotoxicity.
    Tookhi RF; Kabli NA; Huntul MA; Thabit AK
    Intern Emerg Med; 2021 Jun; 16(4):975-979. PubMed ID: 33439417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy.
    Carreno J; Smiraglia T; Hunter C; Tobin E; Lomaestro B
    Int J Antimicrob Agents; 2018 Nov; 52(5):643-650. PubMed ID: 30103003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem.
    Mefford B; Wallace KL; Donaldson JC; Bissell Turpin BD; Sen P; Schadler AD; Liu LJ; Thompson Bastin ML
    Antimicrob Agents Chemother; 2024 May; 68(5):e0108523. PubMed ID: 38606975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam versus vancomycin and piperacillin/tazobactam.
    Shao CH; Tai CH; Lin FJ; Wu CC; Wang JT; Wang CC
    J Formos Med Assoc; 2022 Jan; 121(1 Pt 1):117-125. PubMed ID: 33637370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis.
    Chen XY; Xu RX; Zhou X; Liu Y; Hu CY; Xie XF
    Int Urol Nephrol; 2018 Nov; 50(11):2019-2026. PubMed ID: 29752626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Prevalence of Acute Kidney Injury in Chinese Patients Receiving Vancomycin with Concurrent β-Lactam Antibiotics: A Retrospective Cohort Study.
    Liu K; Zhang Y; Xu X; Wu B; Ni J; Li T; Xing C; Mao H
    Clin Ther; 2021 Oct; 43(10):e319-e351. PubMed ID: 34579971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study.
    Cook KM; Gillon J; Grisso AG; Banerjee R; Jimenez-Truque N; Phillips EJ; Van Driest SL
    J Pediatric Infect Dis Soc; 2019 Jul; 8(3):221-227. PubMed ID: 29590376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model.
    He M; Souza E; Matvekas A; Crass RL; Pai MP
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury.
    Aslan AT; Pashayev T; Dağ O; Akova M
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1953-1961. PubMed ID: 33884515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
    Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
    JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin With Concomitant Piperacillin/Tazobactam vs. Cefepime or Meropenem Associated Acute Kidney Injury in General Ward Patients: A Multicenter Propensity Score-Matched Study.
    Komerdelj IA; Buckley MS; D'Alessio PA; Ziadat DS; Kobic E; Rangan P; Agarwal SK; Tinta NC; Yerondopoulos MJ; Kane-Gill SL
    J Pharm Pract; 2024 Feb; 37(1):80-87. PubMed ID: 36075000
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?
    Balcı C; Uzun Ö; Arıcı M; Hayran SA; Yüce D; Ünal S
    Int J Antimicrob Agents; 2018 Aug; 52(2):180-184. PubMed ID: 29649586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Kidney Injury in Non-Intensive Care and Intensive Care Patients Treated with Vancomycin and Piperacillin-Tazobactam.
    Inage S; Nakamura S; Isoe Y; Okamoto S; Uetake S; Murakami M; Yamaguchi A; Morishima M; Nei T; Ise Y; Katayama S
    J Nippon Med Sch; 2020 May; 87(2):66-72. PubMed ID: 31611508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
    Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
    J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
    Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.